Junji Saruwatari Selected Research

superoxide dismutase 2

1/2014	Impact of the superoxide dismutase 2 Val16Ala polymorphism on the relationship between valproic acid exposure and elevation of γ-glutamyltransferase in patients with epilepsy: a population pharmacokinetic-pharmacodynamic analysis.
1/2013	The combination of mitochondrial low enzyme-activity aldehyde dehydrogenase 2 allele and superoxide dismutase 2 genotypes increases the risk of hypertension in relation to alcohol consumption.
1/2013	Possible associations between antioxidant enzyme polymorphisms and metabolic abnormalities in patients with schizophrenia.
3/2012	Superoxide dismutase 2 Val16Ala polymorphism is a risk factor for the valproic acid-related elevation of serum aminotransferases.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Junji Saruwatari Research Topics

Disease

8	Epilepsy (Aura) 01/2015 - 03/2012
7	Non-alcoholic Fatty Liver Disease 01/2022 - 07/2013
5	Cardiovascular Diseases (Cardiovascular Disease) 03/2022 - 09/2015
5	Type 2 Diabetes Mellitus (MODY) 01/2021 - 09/2013
5	Schizophrenia (Dementia Praecox) 01/2019 - 09/2010
4	Infections 04/2020 - 01/2016
4	Inflammation (Inflammations) 01/2020 - 01/2016
4	Hypertension (High Blood Pressure) 01/2019 - 01/2013
4	Overweight 01/2019 - 01/2013
3	Fibrosis (Cirrhosis) 01/2022 - 12/2018
3	Acute Kidney Injury (Acute Renal Failure) 01/2022 - 01/2019
3	Obesity 01/2020 - 01/2018
3	Coronary Stenosis (Coronary Artery Stenosis) 06/2017 - 01/2016
3	Spasm (Spasms) 06/2017 - 01/2016
3	Diabetic Retinopathy (Retinopathy, Diabetic) 02/2017 - 09/2013
3	Drug-Related Side Effects and Adverse Reactions 01/2017 - 01/2002
2	ST Elevation Myocardial Infarction 02/2022 - 01/2016
2	Glaucoma 11/2021 - 01/2016
2	Kidney Diseases (Kidney Disease) 01/2021 - 01/2019
2	Insulin Resistance 10/2020 - 01/2019
2	Acute Coronary Syndrome 04/2020 - 01/2016
2	Chronic Hepatitis (Chronic Active Hepatitis) 01/2020 - 11/2003
2	Weight Gain 01/2020 - 01/2015
2	Microvascular Angina (Cardiac Syndrome X) 06/2017 - 12/2016
2	Dementia (Dementias) 01/2016 - 09/2015
2	Major Depressive Disorder (Major Depressive Disorders) 01/2016 - 01/2014
2	Hypoglycemia (Reactive Hypoglycemia) 09/2015 - 10/2013
2	Seizures (Absence Seizure) 01/2015 - 03/2014
2	Intellectual Disability (Idiocy) 01/2015 - 01/2014
1	Ischemia 02/2022
1	Reperfusion Injury 02/2022
1	Hypoxia (Hypoxemia) 01/2022
1	Neoplasms (Cancer) 01/2022
1	Chronic Kidney Failure (Chronic Renal Failure) 01/2022
1	Diabetic Nephropathies (Diabetic Nephropathy) 01/2022
1	Fatty Liver 01/2022
1	Chronic Renal Insufficiency 01/2022
1	Hepatocellular Carcinoma (Hepatoma) 01/2022
1	Carcinoma (Carcinomatosis) 12/2021
1	Pancreatic Neoplasms (Pancreatic Cancer) 10/2021
1	Postoperative Pain 01/2021
1	Chemical and Drug Induced Liver Injury 01/2021
1	Metabolically Benign Obesity 10/2020

Drug/Important Bio-Agent (IBA)

8	Pharmaceutical PreparationsIBA 01/2020 - 01/2002
6	Cytochrome P-450 CYP2C19IBA 06/2017 - 03/2011
6	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 06/2017 - 01/2002
5	Aldehyde DehydrogenaseIBA 02/2022 - 01/2013
5	Valproic Acid (Depakote)FDA LinkGeneric 01/2015 - 03/2012
4	Messenger RNA (mRNA)IBA 01/2020 - 01/2016
4	Anticonvulsants (Antiepileptic Drugs)IBA 01/2015 - 10/2012
4	superoxide dismutase 2IBA 01/2014 - 03/2012
3	Biomarkers (Surrogate Marker)IBA 12/2021 - 01/2019
3	Phospholipases (Phospholipase)IBA 01/2020 - 01/2015
3	Lactic Acid (Lactate)FDA LinkGeneric 06/2017 - 01/2016
3	Adenosine Triphosphate (ATP)IBA 06/2017 - 01/2016
3	C-Reactive ProteinIBA 12/2016 - 01/2016
3	Cytochrome P-450 CYP2D6 (CYP2D6)IBA 01/2016 - 12/2006
3	EnzymesIBA 01/2016 - 01/2013
3	Glutathione Transferase (Glutathione S-Transferase)IBA 01/2016 - 01/2013
2	HDL CholesterolIBA 03/2022 - 01/2013
2	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2022 - 01/2020
2	Transforming Growth Factors (Transforming Growth Factor)IBA 11/2021 - 07/2020
2	Acetaminophen (Paracetamol)FDA LinkGeneric 01/2021 - 01/2019
2	LipidsIBA 10/2020 - 09/2013
2	Interleukin-1 (Interleukin 1)IBA 04/2020 - 01/2016
2	Proteins (Proteins, Gene)FDA Link 01/2020 - 01/2018
2	LDL CholesterolIBA 01/2018 - 01/2016
2	Oxidoreductases (Dehydrogenase)IBA 01/2018 - 06/2014
2	Acetylcholine (Acetylcholine Chloride)FDA Link 06/2017 - 12/2016
2	AcidsIBA 06/2017 - 12/2016
2	Paroxetine (Paxil)FDA LinkGeneric 01/2016 - 01/2014
2	Hypoglycemic Agents (Hypoglycemics)IBA 09/2015 - 10/2013
2	SmokeIBA 07/2015 - 01/2015
2	Carbamazepine (Tegretol)FDA LinkGeneric 01/2015 - 03/2014
2	valylvaline (Val-Val)IBA 01/2014 - 01/2013
1	CholesterolIBA 03/2022
1	AldehydesIBA 02/2022
1	Mitochondrial Aldehyde DehydrogenaseIBA 02/2022
1	Carbon MonoxideIBA 01/2022
1	Sorafenib (BAY 43-9006)FDA Link 01/2022
1	AMP-Activated Protein KinasesIBA 01/2022
1	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 01/2022
1	Psychotropic Drugs (Psychoactive Drugs)IBA 01/2022
1	ClusterinIBA 01/2022
1	NF-E2-Related Factor 2IBA 01/2022
1	Cystatin CIBA 12/2021
1	Gemcitabine FDA Link 12/2021
1	Cisplatin (Platino)FDA LinkGeneric 12/2021
1	Extracellular Matrix ProteinsIBA 11/2021
1	Collagen Type I (Type I Collagen)IBA 11/2021
1	Eukaryotic Initiation Factor-2 (EIF 2)IBA 10/2021
1	CreatinineIBA 01/2021
1	AlbuminsIBA 01/2021
1	loxoprofen (CS 600)IBA 01/2021
1	ProstaglandinsIBA 10/2020

Therapy/Procedure

6	Therapeutics 09/2015 - 03/2011
1	Percutaneous Coronary Intervention 02/2022
1	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2022
1	Drug Therapy (Chemotherapy) 12/2021
1	Prostatectomy (Retropubic Prostatectomy) 01/2021